Diabetes Management and Glycemic Control Techniques

Global management of diabetes centres on achieving and maintaining near-normal glycaemia to reduce microvascular and macrovascular complications. Strategies encompass lifestyle modification, blood glucose monitoring, pharmacotherapy and evolving technological solutions. Dietary regulation and exercise remain foundational, while pharmacological advances include tailored insulin regimens, modulators of insulin sensitivity and agents targeting incretin and renal glucose handling pathways. Frequent glucose assessment via capillary self-monitoring or real-time continuous glucose monitoring (CGM) informs therapy adjustments, with metrics such as time in range and HbA1c guiding clinical decisions. Automated insulin delivery systems, integrating CGM with insulin pumps under algorithmic control, represent a shift towards closed-loop approaches that dynamically respond to glycaemic excursions. Emerging innovations in digital health, mobile applications and machine-learning-based decision support are further personalising management. Collectively, these techniques aim to optimise long-term outcomes through precise and adaptive glycaemic control.

Research from Nature Portfolio

Recent trials of fully automated closed-loop systems in adults with type 2 diabetes have demonstrated substantial gains in glucose metrics. In an eight-week, randomised crossover study comparing a proprietary closed-loop mobile application with standard therapy and masked glucose sensing, participants achieved 66.3% time in the target 3.9–10.0 mmol l−1 range versus 32.3% under control, a 35 percentage-point improvement. Mean glucose fell by 3.6 mmol l−1 and HbA1c declined by 1.4%, all without raising hypoglycaemia incidence. These findings underscore the potential of algorithm-driven insulin delivery to enhance efficacy and safety in type 2 diabetes management.

Diabetes Management and Glycemic Control Techniques publication trend

The graph below shows the total number of articles in diabetes management and glycemic control techniques across all publications each year (not limited to Nature Index journals).

Technical terms

HbA1c: Glycated haemoglobin, reflecting average blood glucose over two to three months.

Continuous glucose monitoring (CGM): Technology providing real-time interstitial glucose readings to inform therapy.

Time in range (TIR): Percentage of time glucose remains within a predefined target, typically 3.9–10.0 mmol l−1.

Closed-loop insulin delivery: Automated system coupling CGM with an insulin pump via an algorithm that adjusts insulin dosing in real time.

Glycaemic variability: Degree of fluctuation in blood glucose levels over a given period.

Flash glucose monitoring: Intermittent scanning of a sensor worn under the skin to obtain glucose readings without finger-stick calibration.

References

1. Fully automated closed-loop insulin delivery in adults with type 2 diabetes: an open-label, single-center, randomized crossover trial. Nature Medicine (2023).
2. Closed-loop insulin delivery in suboptimally controlled type 1 diabetes: a multicentre, 12-week randomised trial. The Lancet (2018).
3. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocrine Reviews (2022).
4. Marked improvement in HbA1c following commencement of flash glucose monitoring in people with type 1 diabetes. Diabetologia (2019).
5. Artificial Intelligence for Diabetes Management and Decision Support: Literature Review. Journal of Medical Internet Research (2018).